Malgorzata Gozdecka

Cambridge, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 21 publications

Statin Use and Genetically Predicted HMG-CoA Reductase Inhibition in Relation to Clonal Hematopoiesis.

Statin Use and Genetically Predicted HMG-CoA Reductase Inhibition in Relation to Clonal Hematopoiesis.

Journal: medRxiv : the preprint server for health sciences
Published: July 30, 2026

BCOR mutations define a therapeutic vulnerability to DHODH Inhibition in acute myeloid leukemia.

BCOR mutations define a therapeutic vulnerability to DHODH Inhibition in acute myeloid leukemia.

Journal: Annals of hematology
Published: August 27, 2025

Polθ activity modulates sensitivity to standard therapies in DNMT3A-deficient leukemia.

Polθ activity modulates sensitivity to standard therapies in DNMT3A-deficient leukemia.

Journal: Cell reports. Medicine
Published: October 22, 2024

DNA polymerase theta-mediated DNA repair is a functional dependency and therapeutic vulnerability in DNMT3A deficient leukemia cells.

DNA polymerase theta-mediated DNA repair is a functional dependency and therapeutic vulnerability in DNMT3A deficient leukemia cells.

Journal: bioRxiv : the preprint server for biology
Published: October 16, 2024

Posttranscriptional depletion of ribosome biogenesis factors engenders therapeutic vulnerabilities in NPM1-mutant AML.

Posttranscriptional depletion of ribosome biogenesis factors engenders therapeutic vulnerabilities in NPM1-mutant AML.

Journal: Blood
Published: July 12, 2024

Telomere attrition becomes an instrument for clonal selection in aging hematopoiesis and leukemogenesis.

Telomere attrition becomes an instrument for clonal selection in aging hematopoiesis and leukemogenesis.

Journal: Nature genetics
Published: June 09, 2024

Mitochondrial metabolism sustains DNMT3A-R882-mutant clonal haematopoiesis.

Mitochondrial metabolism sustains DNMT3A-R882-mutant clonal haematopoiesis.

Journal: Nature
Published: March 19, 2024

Preleukemic single-cell landscapes reveal mutation-specific mechanisms and gene programs predictive of AML patient outcomes.

Preleukemic single-cell landscapes reveal mutation-specific mechanisms and gene programs predictive of AML patient outcomes.

Journal: Cell genomics
Published: April 14, 2023

Pharmacological inhibition of METTL3 impacts specific haematopoietic lineages.

Pharmacological inhibition of METTL3 impacts specific haematopoietic lineages.

Journal: Leukemia
Published: April 06, 2023

Transcriptional variability accelerates preleukemia by cell diversification and perturbation of protein synthesis.

Transcriptional variability accelerates preleukemia by cell diversification and perturbation of protein synthesis.

Journal: Science advances
Published: August 03, 2022

Publisher Correction: UTX-mediated enhancer and chromatin remodeling suppresses myeloid leukemogenesis through noncatalytic inverse regulation of ETS and GATA programs.

Publisher Correction: UTX-mediated enhancer and chromatin remodeling suppresses myeloid leukemogenesis through noncatalytic inverse regulation of ETS and GATA programs.

Journal: Nature genetics
Published: June 14, 2022

Small-molecule inhibition of METTL3 as a strategy against myeloid leukaemia.

Small-molecule inhibition of METTL3 as a strategy against myeloid leukaemia.

Journal: Nature
Published: December 18, 2020
Showing 1-12 of 21

Last Updated: 09/26/2026